<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05052801</url>
  </required_header>
  <id_info>
    <org_study_id>20210096</org_study_id>
    <nct_id>NCT05052801</nct_id>
  </id_info>
  <brief_title>Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression</brief_title>
  <acronym>FORTITUDE-101</acronym>
  <official_title>A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With FGFR2b Overexpression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to compare efficacy of bemarituzumab combined with&#xD;
      oxaliplatin and 5-fluorouracil (5-FU) (mFOLFOX6) to placebo plus mFOLFOX6 as assessed by&#xD;
      overall survival (OS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 3.5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Up to approximately 3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to approximately 3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants who Experience a Treatment-emergent Adverse Event (TEAE)</measure>
    <time_frame>Up to approximately 3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to approximately 3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>Up to approximately 3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Score in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30)</measure>
    <time_frame>Up to approximately 3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Score in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30)</measure>
    <time_frame>Baseline up to approximately 3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stomach Cancer Related Symptom Mean Score as Measured by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Stomach (EORTC-QLQ-STO22)</measure>
    <time_frame>Up to approximately 3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Stomach Cancer Related Symptom Score as Measured by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Stomach (EORTC-QLQ-STO22)</measure>
    <time_frame>Baseline up to approximately 3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Score in Visual Analogue Scale (VAS) as Measured by the EuroQol 5-dimensional 5-levels (EQ-5D-5L)</measure>
    <time_frame>Up to approximately 3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Score in Visual Analogue Scale (VAS) as Measured by the EuroQol 5-dimensional 5-levels (EQ-5D-5L)</measure>
    <time_frame>Baseline up to approximately 3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration in Stomach Cancer Related Symptom Score as Measured by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Stomach (EORTC-QLQ-STO22)</measure>
    <time_frame>Up to approximately 3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) Score</measure>
    <time_frame>Up to approximately 3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration in Visual Analogue Scale (VAS) as Measured by the EuroQol 5-dimensional 5-levels (EQ-5D-5L) Score</measure>
    <time_frame>Up to approximately 3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration in Physical Function Score as Measured by a Subscale of European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30)</measure>
    <time_frame>Day 1 up to approximately 3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of Bemarituzumab in Combination with mFOLFOX6 in Plasma</measure>
    <time_frame>Day 1 up to approximately 3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Concentration at the End of a Dose Interval (Ctrough) of Bemarituzumab in Combination with mFOLFOX6 in Plasma</measure>
    <time_frame>Day 1 up to approximately 3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with an Anti-bemarituzumab Antibody Formation</measure>
    <time_frame>Day 1 up to approximately 3.5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">516</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Gastroesophageal Junction Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Bemarituzumab with mFOLFOX6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo with mFOLFOX6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bemarituzumab</intervention_name>
    <description>Intravenous (IV) infusion</description>
    <arm_group_label>Bemarituzumab with mFOLFOX6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFOLFOX6</intervention_name>
    <description>mFOLFOX6 administered as a combination of oxaliplatin and leucovorin as IV infusions. 5-FU administered as bolus followed by additional administration as IV infusion.</description>
    <arm_group_label>Bemarituzumab with mFOLFOX6</arm_group_label>
    <arm_group_label>Placebo with mFOLFOX6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Placebo with mFOLFOX6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults with unresectable, locally advanced or metastatic gastric or gastroesophageal&#xD;
             junction cancer not amenable to curative therapy&#xD;
&#xD;
          -  Confirmed fibroblast growth factor receptor 2b (FGFR2b) overexpression by&#xD;
             immunohistochemistry (IHC) (central testing result)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) less than or equal to 1&#xD;
&#xD;
          -  Measurable, evaluable, or non-evaluable disease as long as evaluable by Response&#xD;
             Evaluation Criteria in Solid Tumors (RECIST) version 1.1&#xD;
&#xD;
          -  Participant has no contraindications to mFOLFOX6 chemotherapy&#xD;
&#xD;
          -  Adequate organ and bone marrow function:&#xD;
&#xD;
               -  absolute neutrophil count greater than or equal to 1.5 times 10^9/L&#xD;
&#xD;
               -  platelet count greater than or equal to 100 times 10^9/L&#xD;
&#xD;
               -  hemoglobin greater than or equal to 9 g/dl&#xD;
&#xD;
               -  aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 3&#xD;
                  times the upper limit of normal (ULN) (or less than 5 times ULN if liver&#xD;
                  involvement). Total bilirubin less than 1.5 times ULN (or less than 2 times ULN&#xD;
                  if liver involvement); with the exception of participants with Gilbert's disease)&#xD;
&#xD;
               -  calculated or measured creatinine clearance (CrCl) of greater than or equal to 30&#xD;
                  mL/minute calculated using the formula of Cockcroft and Gault&#xD;
&#xD;
               -  international normalized ratio (INR) or prothrombin time (PT) less than 1.5 times&#xD;
                  ULN except for participants receiving anticoagulation, who must be on a stable&#xD;
                  dose of anticoagulant therapy for 6 weeks prior to enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment for metastatic or unresectable disease (Note: prior adjuvant or&#xD;
             neo-adjuvant therapy for local disease is allowed if ended more than 6 months of 1st&#xD;
             dose)&#xD;
&#xD;
          -  Prior treatment with any selective inhibitor of fibroblast growth factor - fibroblast&#xD;
             growth factor receptor (FGF-FGFR) pathway&#xD;
&#xD;
          -  Known human epidermal growth factor receptor 2 (HER2) positive&#xD;
&#xD;
          -  Untreated or symptomatic central nervous system (CNS) disease or brain metastases&#xD;
&#xD;
          -  Peripheral sensory neuropathy greater than or equal to Grade 2&#xD;
&#xD;
          -  Clinically significant cardiac disease&#xD;
&#xD;
          -  Other malignancy within the last 2 years (exceptions for definitively treated disease)&#xD;
&#xD;
          -  Chronic or systemic ophthalmological disorders&#xD;
&#xD;
          -  Major surgery or other investigational study within 28 days prior to first dose of&#xD;
             study treatment&#xD;
&#xD;
          -  Palliative radiotherapy within 14 days prior to the first dose of study treatment&#xD;
&#xD;
          -  Abnormalities of the cornea that may pose an increased risk of developing a corneal&#xD;
             ulcer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
    <email>medinfo@amgen.com</email>
  </overall_contact>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 13, 2021</study_first_submitted>
  <study_first_submitted_qc>September 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastric Cancer</keyword>
  <keyword>Gastroesophageal Junction Adenocarcinoma</keyword>
  <keyword>Bemarituzumab</keyword>
  <keyword>FGFR2b Overexpression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bemarituzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.</ipd_access_criteria>
    <ipd_url>https://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

